Sugi Predict

Sugi Predict / Compounds / SCHEMBL4185704

SCHEMBL4185704

SCHEMBL4185704

FC(F)(F)Oc1cccc(-c2nnc(-c3ccccc3NCc3ccc4c(c3)OCO4)[nH]2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP1 O94782 2/20 0.46
▸ WDR48 Q8TAF3 2/20 0.46
▸ KDR P35968 2/20 0.42
▸ FLT1 P17948 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ PIM1 P11309 2/20 0.40
▸ PIM2 Q9P1W9 1/20 0.40
▸ HPGD P15428 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4169643 0.95 KDR (0.42) USP1WDR48KDRFLT1CLK4
SCHEMBL4174943 0.88 CLK4 (0.53) CLK4MEN1KMT2ANPC1LMNA
SCHEMBL4181158 0.86 USP1 (0.49) USP1WDR48KDRFLT1MEN1
SCHEMBL4176749 0.83 USP1 (0.49) USP1WDR48KDRCLK4MEN1
SCHEMBL4188204 0.81 KDR (0.44) USP1WDR48KDRFLT1RXFP1
SCHEMBL4188197 0.81 MEN1 (0.47) KDRFLT1CLK4MEN1KMT2A
SCHEMBL4176759 0.80 KDR (0.41) KDRFLT1PIM1CYP1A2CYP3A4
SCHEMBL4172244 0.77 KDR (0.47) USP1WDR48KDRFLT1MEN1
SCHEMBL4185705 0.76 DYRK1A (0.40) MEN1KMT2ANPC1LMNARAB9A
SCHEMBL4178035 0.76 PDE5A (0.48) KDRCLK4MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 — — US disclosed
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 — — US disclosed
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 — — US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 — — US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 — — US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL USP1 3860/4885WDR48 2765/4885KDR 3284/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL USP1 3860/4885WDR48 2765/4885KDR 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.